UBS Group
PRCT icon

UBS Group’s Procept Biorobotics PRCT Stock Holding History

UBS Group’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.78M Sell
432,993
-71,500
-14% -$1.79M ﹤0.01% 3486
2026
Q1 		$12.6M Sell
504,493
-548,451
-52% -$15.5M ﹤0.01% 3101
2025
Q4 		$33.1M Buy
1,052,944
+108,399
+11% +$3.59M 0.01% 2067
2025
Q3 		$33.7M Buy
944,545
+532,530
+129% +$24.3M 0.01% 2023
2025
Q2 		$23.7M Buy
412,015
+200,415
+95% +$11.3M ﹤0.01% 2194
2025
Q1 		$12.3M Buy
211,600
+57,487
+37% +$3.93M ﹤0.01% 2828
2024
Q4 		$12.4M Buy
154,113
+62,619
+68% +$5.35M ﹤0.01% 2824
2024
Q3 		$7.33M Buy
91,494
+21,899
+31% +$1.56M ﹤0.01% 2675
2024
Q2 		$4.25M Buy
69,595
+16,749
+32% +$996K ﹤0.01% 3023
2024
Q1 		$2.61M Buy
52,846
+20,205
+62% +$962K ﹤0.01% 3670
2023
Q4 		$1.37M Buy
32,641
+29,205
+850% +$995K ﹤0.01% 4211
2023
Q3 		$113K Sell
3,436
-15,547
-82% -$530K ﹤0.01% 5756
2023
Q2 		$671K Sell
18,983
-33,634
-64% -$1.11M ﹤0.01% 4565
2023
Q1 		$1.49M Buy
52,617
+45,605
+650% +$1.61M ﹤0.01% 3726
2022
Q4 		$291K Buy
7,012
+5,189
+285% +$223K ﹤0.01% 5155
2022
Q3 		$75K Buy
1,823
+1,023
+128% +$40.8K ﹤0.01% 5972
2022
Q2 		$26K Sell
800
-19,706
-96% -$717K ﹤0.01% 6559
2022
Q1 		$718K Buy
20,506
+1,837
+10% +$44.2K ﹤0.01% 4416
2021
Q4 		$467K Buy
18,669
+18,052
+2,926% +$668K ﹤0.01% 5036
2021
Q3 		$24K Buy
+617
New +$23.7K ﹤0.01% 6975

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

UBS Group's PRCT Position: Q2 2026 in Review

UBS Group reduced its Procept Biorobotics (PRCT) stake by 14% in Q2 2026, selling an estimated $1.79M and leaving 432,993 shares worth $9.78M. The position accounts for ﹤0.01% of the portfolio, ranked #3486.

UBS Group first reported a position in PRCT in Q3 2021 and has held it in 20 quarters since. The position peaked at $33.7M in Q3 2025. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • UBS Group held 432,993 shares of Procept Biorobotics worth $9.78M as of Q2 2026.
  • UBS Group sold 71,500 Procept Biorobotics shares in Q2 2026, an estimated $1.79M.
  • Procept Biorobotics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3486 holding.
  • UBS Group first reported a position in Procept Biorobotics in Q3 2021 and has held it in 20 quarters since.
  • UBS Group's Procept Biorobotics position peaked at $33.7M in Q3 2025.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.